Sky Quarry and Agios Pharma Stocks Surge on Oil Tensions and FDA Milestone

Key Facts

Amid a landscape where geopolitical tensions and regulatory milestones drive market sentiment, Sky Quarry and Agios Pharma recorded significant gains. Sky Quarry's stock climbed as crude oil prices reacted to shipping disruptions in the Strait of Hormuz and elevated short interest levels. Simultaneously, Agios Pharma shares spiked 15% following the FDA's decision to grant Priority Review for mitapivat, a promising candidate for treating sickle cell disease, marking a critical fundamental breakthrough for the biotech firm.

The rally in Sky Quarry underscores the sensitivity of energy-linked equities to geopolitical risks in vital maritime corridors, coinciding with shifts in global energy reserves. Per market data, the EIA Weekly Petroleum Report showed a stock decrease of 3.775 million barrels in early July 2026, providing further tailwinds for oil prices. Meanwhile, the FDA's Priority Review places Agios Pharma on an accelerated path toward potential commercialization, a catalyst that typically triggers significant valuation adjustments compared to industry peers.

Investors should closely monitor crude oil price stability and its ongoing impact on small-cap energy stocks, as price levels remain vulnerable to sudden supply shocks. For Agios Pharma, the subsequent stages of the FDA review process will serve as the primary driver for the stock's trajectory. On the macroeconomic front, traders are looking toward upcoming US employment and growth data to gauge consumer strength, which may indirectly influence risk appetite across the energy and healthcare sectors.